Opening a new era of diagnostics

with Artificial Intelligence

LIVERFASt™ is a blood based diagnostic test that combines 10 biomarkers and algorithm technology to determine the fibrosis, activity and steatosis stages of the liver.

Biomarkers

  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • AST (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
LIVERFACt is a component of LIVERFASt™ that utilizes only 6 out of the 10 biomarkers to provide results for fibrosis and activity stages of the liver. LIVERFACt enables early diagnosis of liver disease in patients with Hepatitis B and Hepatitis C.

Biomarkers

  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
SteatoTEST applies the similar 10 biomarkers that LIVERFASt™ utilizes and provides results for the staging of liver steatosis or also known as fatty liver.

Biomarkers

  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • AST (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
LIVERFASt select is a risk stratification tool for fatty liver disease that utilizes a combination of basic blood biomarkers and algorithm technology.

Biomarkers

  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
HealthFACTR employs technology to predict risk – providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease.

Biomarkers

  • LDL
  • HDL
  • Body Fat Percentage
  • Triglyceride
  • Total Cholesterol
LIVERFASt™ is a blood based diagnostic test that combines 10 biomarkers and algorithm technology to determine the fibrosis, activity and steatosis stages of the liver.

Biomarkers

  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • AST (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
An advance algorithm assesses serum biomarkers1 and patient information to indicate if a patient is in risk of COVID-19 infection within 24-48 hours**.
  • 1 in every 5 people infected require hospital care
  • No signs and symptoms for as long as 14days
  • No Vaccine is currently available for COVID-19
  • No antiviral medication is specific for the treatment of COVID-19

EARLY SCREENING ALLOWS FOR EARLY INTERVENTION

EARLY INTERVENTION SAVES LIVES

Biomarkers

  • LDL
  • HDL
  • Body Fat Percentage
  • Triglyceride
  • Total Cholesterol

Diagnostic Tests

Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups

Lorem ipsum is placeholder text commonly used in the graphic, print.

Diagnostic Tests

Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups

Lorem ipsum is placeholder text commonly used in the graphic, print.

0 +
0 +
0 +

Screening Tests

Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups

Lorem ipsum is placeholder text commonly used in the graphic, print.

0 +
0 +

Analytic Tool

Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups

Lorem ipsum is placeholder text commonly used in the graphic, print.
0 +

Analytic Tool

Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups

Lorem ipsum is placeholder text commonly used in the graphic, print.
0 +
Product description:
LIVERFASt™ is a blood based diagnostic test that combines 10 biomarkers and algorithm technology to determine the fibrosis, activity and steatosis stages of the liver.
Biomarker Required:
  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • AST (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
Score Charts:
Product description:
LIVERFACt is a component of LIVERFASt™ that utilizes only 6 out of the 10 biomarkers to provide results for fibrosis and activity stages of the liver. LIVERFACt enables early diagnosis of liver disease in patients with Hepatitis B and Hepatitis C.
Biomarker Required:
  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
Score Charts:
Product description:
SteatoTEST applies the similar 10 biomarkers that LIVERFASt™ utilizes and provides results for the staging of liver steatosis or also known as fatty liver.
Biomarker Required:
  • Alpha-2-Macroglobulin
  • Haptoglobin
  • Apolipoprotein A1
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • AST (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
Score Charts:
Product description:
LIVERFASt select is a risk stratification tool for fatty liver disease that utilizes a combination of basic blood biomarkers and algorithm technology.
Biomarker Required:
  • Total Bilirubin
  • GGT
  • ALT (P5P)
  • Fasting Glucose
  • Triglyceride
  • Total Cholesterol
Score Charts:
Product description:
HealthFACTR employs technology to predict risk – providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease.
Biomarker Required:
  • LDL Cholesterol
  • HDL Cholesterol
  • Body Fat Percentage
  • Triglyceride
  • Total Cholesterol
Score Charts:
Example cases:
Product description:
Lorem ipsum is placeholder text commonly used in the graphic, print, and publishing industries for previewing layouts and visual mockups.
*
*